Creo Medical ( (GB:CREO) ) has issued an announcement.
Creo Medical Group PLC has announced the commercial launch of its SpydrBlade Flex technology in the UK and Europe, marking its first customer at St Mark’s Hospital in London, a leading NHS Endoscopy unit. This launch signifies a significant step in Creo’s strategy to expand its presence in the minimally invasive surgical endoscopy market, with plans to extend into the US following regulatory approvals. The SpydrBlade Flex, along with the Speedboat UltraSlim, is expected to improve patient care by shifting procedures from the operating theatre to the endoscopy room, potentially reducing surgical waiting lists globally and enhancing treatment options for various conditions.
More about Creo Medical
Creo Medical Group PLC is a medical device company that specializes in the development and commercialization of minimally invasive electrosurgical devices, focusing on advanced energy solutions for endoscopy. The company aims to enhance patient outcomes through its CROMA powered by Kamaptive technology, which integrates multi-modal energy sources for procedures such as resection, dissection, coagulation, and ablation.
YTD Price Performance: -33.97%
Average Trading Volume: 684,608
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £52.8M
Find detailed analytics on CREO stock on TipRanks’ Stock Analysis page.